Back

Explore every episode of the podcast Decera Clinical Education Infectious Disease Podcast

Dive into the complete episode list for Decera Clinical Education Infectious Disease Podcast. Each episode is cataloged with detailed descriptions, making it easy to find and explore specific topics. Keep track of all episodes from your favorite podcast and never miss a moment of insightful content.

Rows per page:

1–50 of 506

TitlePub. DateDuration
Persisting in HIV Care: Considerations for People With Substance Use Disorders13 Sep 202400:15:47

In this episode, Alexander Wong, MD, FRCPC, discusses how to optimize treatment and engagement in care for individuals with HIV and substance use disorder, including: 

  • Barriers to care for persons with substance use disorder 
  • Colocating HIV and other services (eg, addiction care medicine, social services) 
  • Leveraging a multidisciplinary approach to care 
  • Integrating a low-barrier model to foster an environment of open discussion 
  • Best practices for opioid agonist therapy implementation
  • Considerations for cultural dynamics to provide personalized treatment plans
  • Importance of supporting his team members 

Presenter

Alexander Wong, MD, FRCPC
Associate Professor
Division of Infectious Diseases
Department of Medicine
University of Saskatchewan
Regina, Saskatchewan, Canada

 

Link to full program:
https://bit.ly/3xicSeF

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Integrating New Data From AIDS 2024: Pharmacist Perspectives30 Aug 202400:18:22

In this episode, Jennifer Cocohoba, PharmD, AAHIVP, and David Koren, PharmD, MPH, AAHIVP, FIDSA, cover the most impactful LA ART and LA PrEP clinical studies presented at AIDS 2024, including:

  • The PURPOSE 1 study of twice-yearly lenacapavir injections vs daily oral tenofovir as PrEP in cisgender women
  • An open-label extension of HPTN 084 evaluating LA CAB safety during pregnancy
  • 48-week data from the IMPAACT 2017/MOCHA study of LA CAB + RPV in adolescents with HIV
  • A substudy of FLAIR evaluating the efficacy, safety, and tolerability of SC self-administration of LA CAB + RPV
     

Presenters:

Jennifer Cocohoba, PharmD, AAHIVP
Professor of Clinical Pharmacy
Department of Clinical Pharmacy
University of California San Francisco School of Pharmacy
San Francisco, California

David Koren, PharmD, MPH, AAHIVP, FIDSA
Adjunct Clinical Professor
Temple University School of Pharmacy
Clinical Pharmacist Specialist
Temple University Health System
Philadelphia, Pennsylvania

To access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.  

See the full program here.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Optimizing PBC Pruritus Care in the Clinic29 Jul 202400:21:06

In this episode, Stuart C. Gordon, MD, FACP, FACG, AGAF, FAASLD; Marlyn J. Mayo, MD; and Brenda Remo discuss strategies for optimizing PBC pruritus care in the clinic setting.

Listen to their conversation on how important it is to ask patients about their pruritus, validate their symptoms and feelings, and offer treatment options framed with realistic expectations.

Presenters:

Stuart C. Gordon, MD, FACP, FACG, AGAF, FAASLD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health 
Detroit, Michigan

Marlyn J. Mayo, MD
Professor of Internal Medicine
Division of Digestive & Liver Diseases
University of Texas Southwestern
Dallas, Texas

Brenda Remo
Person living with PBC

Downloadable slides: 
https://bit.ly/3LHHiuf

Program: 
https://bit.ly/4fBLQ3l

To get access to all of our new podcast episodes, subscribe to the CCO podcast channels on Apple Podcasts, Google Podcasts, or Spotify.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Q&A on HIV PrEP: Episode 1 on Transgender Individuals and Racial and Ethnic Minority Men Who Have Sex With Men08 Sep 202300:35:33

In this episode, Raphael J. Landovitz, MD, MSc, and Hyman Scott, MD, MPH, discuss key considerations for PrEP uptake in transgender individuals and racial and ethnic minority men who have sex with men, including: 

  • Misconceptions about PrEP eligibility 
  • Strategies to improve lab monitoring on PrEP 
  • Leveraging patient navigators and clinic staff to expand PrEP access
  • Data on PrEP efficacy in key populations (eg, transgender men, people who inject drugs)
  • Considerations for prescribing on-demand and same-day PrEP 
  • Addressing healthcare professional hesitancy to prescribe PrEP
  • US Preventive Services Task Force PrEP guideline updates
  • Bundling sexually transmitted infection services with PrEP

Faculty

Raphael J. Landovitz, MD, MSc
Professor of Medicine
Division of Infectious Diseases
David Geffen School of Medicine
University of California, Los Angeles
Director, UCLA Center for Clinical AIDS Co-Director, Center for HIV Identification, Prevention, and Treatment Services 
Los Angeles, California

Hyman Scott, MD
Assistant Clinical Professor
Department of Medicine
University of California, San Francisco
Clinical Research Medical Director
Bridge HIV
San Francisco Department of 
Public Health
San Francisco, California

Link to full program: 
https://bit.ly/3PZGYdR


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

RSV Recommendations From ACIP: How to Apply Them in Your Older Adults08 Sep 202300:11:55

In this episode, Angela Branche, MD, discusses the Advisory Committee on Immunization Practices recommendations for RSV vaccines in older adults, including: 

  • Use of shared clinical decision-making 
  • How to approach the conversation about the RSV vaccine with patients
  • Key populations who may benefit the most, such as those at risk for severe RSV disease (eg, increasing age and persons who are frail or have cardiopulmonary comorbidities)

Faculty: 

Angela Branche, MD

Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
University of Rochester
Rochester, New York


Link to full program: https://bit.ly/3nb25xe


Link to downloadable slides: https://bit.ly/3nb25xe


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Challenging Scenarios: Managing Virologic Failure in a Heavily Treatment–Experienced Patient22 Aug 202300:19:32

In this episode, Renslow Sherer, MD, discusses managing virologic failure in a person living with HIV who is heavily treatment experienced, including:

  • Guideline recommendations for selecting a new ART regimen
  • Options for patients with multidrug-resistant HIV from existing drug classes and novel mechanisms of action with no cross-resistance
  • Data from TMB-301 and TMB-311 for ibalizumab, BRIGHTE for fostemsavir, and CAPELLA for lenacapavir on the use of these agents for people living with HIV who are heavily treatment experienced with multidrug-resistant HIV

Presenter:

Renslow Sherer, MD
Director
International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois

To download the slides:
https://bit.ly/3OcqxIE

To view the full online program:
https://bit.ly/3ZjSFhg


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

PrEP Talks: Uptake in Cisgender Women08 Aug 202300:17:13

In this episode, Oni Blackstock, MD, MHS, and Brittany Williams, PhD,discuss key considerations to pre-exposure prophylaxis (PrEP) uptake in cisgender women, including: 

  • The misconception by patients and healthcare professionals (HCP) that cisgender women are at low risk for HIV 
  • Reframing HIV prevention from “risks” to “reasons” such as promoting self-care and taking control of one’s own sexual health
  • CDC PrEP guidance recommendations 
  • Increasing PrEP awareness by sharing PrEP experiences with others in the community
  • The importance of community representation in PrEP marketing and campaigns 
  • Challenges with finding HCPs who prescribe PrEP for cisgender women
  • Promoting self-advocacy when seeking care, including HIV prevention 
  • Strategies for patients to engage with their HCPs to learn about and obtain PrEP 
  • Available resources for PrEP coverage

 

Faculty: 

 

Oni Blackstock, MD, MHS
Founder & Executive Director

Health Justice

New York, New York

 

Brittany Williams, PhD
Assistant Professor of Higher Education and Student Affairs Administration

Department of Education

University of Vermont

Burlington, Vermont

 

Link to full program: https://bit.ly/3PZGYdR


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Long-Acting Lipoglycopeptides for Skin and Soft Tissue Infections : Implementation Into Practice08 Aug 202300:18:53

In this episode, Kyle Molina, PharmD, BCIDP, discusses key considerations for successful implementation of long-acting lipoglycopeptides into clinical practice. Listen as he gives perspectives on:

  • Reasons to consider use of long-acting lipoglycopeptides (eg, poor adherence to oral antibiotics, PICC-related costs and complications)
  • Data supporting and challenging cost effectiveness of long-acting lipoglycopeptides 
  • Identifying the target patient population
  • Selecting the right location to provide long-acting lipoglycopeptides 
  • Strategies to maximize institutional impact with key stakeholders (eg, hospital avoidance, reduced ED and hospital length of stay) 
  • Key characteristics of available long-acting lipoglycopeptides 
  • Addressing logistical challenges, including navigating the reimbursement process

 

Faculty:

Kyle Molina, PharmD, BCIDP
Infectious Diseases Clinical Pharmacist
Scripps Green Hospital
La Jolla, California

Link to full program: 


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

People of Childbearing Potential and Their Infants: Overcoming HBV Barriers03 Aug 202300:33:31

In this episode, Joseph Ahn, MD, MS, MBA; Christina Delacruz Leyson, MD; and Alice Chan, a person who experienced pregnancy as a person living with chronic hepatitis B, discuss solutions for overcoming barriers to HBV care in people of childbearing potential and their infants, including:

  • HBV screening and vaccination in pregnancy
  • Management of pregnant people who are HBsAg positive
  • Infant care
  • Breastfeeding

Presenters: 

Joseph Ahn, MD, MS, MBA
Professor of Medicine, Section Chief
Division of Gastroenterology and Hepatology
Oregon Health & Science University
Portland, Oregon

Christina Delacruz Leyson, MD
Associate Professor
Medical Director, Liver Transplant Program
Program Director, Hepatology Fellowship
University of Kentucky
Lexington, Kentucky

Alice Chan, person living with chronic hepatitis B

Link to downloadable slides:
https://bit.ly/3rXLTC7

Link to program: 
https://bit.ly/3L3Kz6l


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Managing ART Failure: Answering the Questions03 Aug 202300:48:55

In this episode, Daniel R. Kuritzkes, MD, and Cristina Mussini, MD, discuss managing ART failure, including:

  • The definitions of virologic blips, low-level viremia, and virologic failure on ART
  • The infrequency of failure with resistance on first-line INSTI-based ART and the instances where this has occurred with BIC- and DTG-based ART in clinical trials and in the real world
  • The potential reasons for ART failure, including patient/adherence-related factors, HIV-related factors, and regimen-related factors
  • The impact of adherence on viral suppression with BIC- and DTG-based ART
  • Drug-drug interactions as a reason for failure of first-line INSTI-based ART
  • What to do if someone is experiencing virologic failure requiring an ART change
  • The use of proviral DNA testing in patients with viral suppression or low-level viremia with ART treatment experience
  • The impact of high HIV-1 RNA on ART effectiveness
  • The impact of NRTI resistance, including the M184V and K65R mutations, on the effectiveness of BIC- and DTG-based ART
  • Strategies to encourage and measure patient adherence to ART 

Presenters

Daniel R. Kuritzkes, MD
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Boston, Massachusetts

Cristina Mussini, MD
Professor
Department of Infectious Diseases
University of Modena and 
Reggio Emilia
Modena, Italy

Link to full program: https://bit.ly/3HPu4Lk


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Challenging Scenarios: Managing a First ART Failure26 Jul 202300:18:04

In this episode, Renslow Sherer, MD, discusses managing a first ART failure in the setting of COVID-19, including:

  • Guideline recommendations for resistance testing
  • Guideline recommendations for selecting a new ART regimen
  • Data on retained efficacy of NRTIs in second-line regimens in the EARNEST and NADIA studies
  • Consideration of drug‒drug interactions between ART and COVID-19 treatment

Presenter: 
Renslow Sherer, MD
Director 
International HIV Training Center 
Professor of Medicine 
Section of Infectious Diseases and Global Health 
Department of Medicine 
University of Chicago 
Chicago, Illinois 

To download the slides: https://bit.ly/3OcqxIE 

To view the full online program: https://bit.ly/3ZjSFhg


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

PrEP Talks: Uptake in Racial and Ethnic Minority Men Who Have Sex With Men and Transgender Individuals19 Jul 202300:20:42

In this episode, Kenyon R. Farrow and Raphael J. Landovitz, MD, MSc, discuss key considerations to PrEP uptake in transgender individuals and racial and ethnic minority men who have sex with men, including: 

  • Rates of HIV diagnoses in Black and Brown communities
  • Issues stalling success in HIV prevention (eg, stigma, healthcare coverage, and administration and operational barriers)
  • Considerations for healthcare professionals when discussing PrEP with patients
  • Importance of representation (eg, racial and ethnic minority people, transgender people) at clinic offices
  • Promoting cultural humility to build strong patient-provider relationships

Faculty: 

Kenyon R. Farrow
Vice President of Policy
Point Source Youth
Contributing Editor
TheBody.com
Cleveland, Ohio

Raphael J. Landovitz, MD, MSc
Professor of Medicine
Division of Infectious Diseases
David Geffen School of Medicine
University of California, Los Angeles
Director, UCLA Center for Clinical AIDS Co-Director, Center for HIV Identification, Prevention, and Treatment Services
Los Angeles, California

Link to full program:
https://bit.ly/3PZGYdR


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

PrEP Initiation: Answering the Questions13 Jul 202300:51:29

In this episode, Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, and Meredith Clement, MD, discuss PrEP initiation, including:

  • The importance of taking a sexual history and getting to know your patient
  • Recommendations for who should be considered for PrEP
  • Practicalities of PrEP initiation including laboratory assessments, interview and physical exam, evaluating concomitant medications, counseling, and prescribing
  • Summary of PrEP eligibility by regimen
  • Review of the clinical trial and real-world data for each PrEP modality
  • The likelihood of cross-resistance between PrEP options and ART options if someone were to become infected with HIV while receiving PrEP
  • Time to effective concentrations of PrEP after initiation
  • Whether there are data for on-demand dosing of FTC/TAF
  • Recommendations for FTC/TDF on demand for heterosexual cisgender men
  • Individualizing PrEP for each person to increase the likelihood of adherence, persistence, and efficacy
  • Recommendations for the use of LA CAB for PrEP during pregnancy and in people of childbearing potential
  • STI and point-of-care testing for people receiving PrEP
  • The possibility of implantable PrEP in the future

Presenters:

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Professor and Director
The Desmond Tutu HIV Centre University of Cape Town
Cape Town, South Africa

Meredith Clement, MD 
Assistant Professor
Section of Infectious Diseases
Louisiana State University Health Sciences Center
University Medical Center
New Orleans, Louisiana 

Link to full program:
https://bit.ly/3HPu4Lk


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Patient Experience With Cholestatic Pruritus in PBC29 Jul 202400:13:05

In this episode, Stuart C. Gordon, MD, FACP, FACG, AGAF, FAASLD; Marlyn J. Mayo, MD; and Brenda Remo discuss the patient experience with cholestatic pruritus in PBC.

Listen to their conversation on how people describe the experience of cholestatic pruritus, the extent to which pruritus negatively affects quality of life, and the importance of educating healthcare professionals on this important symptom of PBC.

Presenters:

Stuart C. Gordon, MD, FACP, FACG, AGAF, FAASLD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health 
Detroit, Michigan

Marlyn J. Mayo, MD
Professor of Internal Medicine
Division of Digestive & Liver Diseases
University of Texas Southwestern
Dallas, Texas

Brenda Remo
Person living with PBC

Downloadable slides: 
https://bit.ly/3LHHiuf

Program: 
https://bit.ly/4fBLQ3l

To get access to all of our new podcast episodes, subscribe to the CCO podcast channels on Apple Podcasts, Google Podcasts, or Spotify.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Viral Hepatitis Update: CCO Independent Conference Coverage of EASL 202311 Jul 202300:47:15

In this episode, Stefan Zeuzem, MD, discusses new data on viral hepatitis presented at EASL 2023, including:

  • Hepatitis B virus
    • Durability of response with bepirovirsen
    • HBsAg loss with siRNA VIR-2218 combined with either VIR-3434 (novel monoclonal antibody) or pegIFN-alfa
  • Hepatitis delta virus
    • 96-week follow-up of immediate vs delayed bulevirtide
    • Off-treatment response for lonafarnib + ritonavir ± pegIFN-alfa 
    • Safety and efficacy outcomes with siRNA JNJ-3989 + nucleos(t)ide analogue
  • Hepatitis C virus
    • Collaborative service at opiate substitution treatment clinic to improve linkage to care in Ireland
    • Nurse-led test-and-treat program to increase screening and diagnosis at female prisons in the United Kingdom
    • FIND-C study using machine learning to improve screening-to-diagnosis ratio using clinical factors and social determinants of health

Presenter:

Stefan Zeuzem, MD
Professor of Medicine 
Chief, Department of Medicine 
JW Goethe University Hospital 
Frankfurt, Germany

Link to full program: 

https://bit.ly/3JQQj3J


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Treatment of Skin and Soft Tissue Infections11 Jul 202300:27:38

In this episode, Kyle Molina, PharmD, BCIDP, provides an overview of treatment of skin and soft tissue infections (SSTIs) and challenges in practice. Listen as he gives perspectives on:

  • Guideline recommendations for treatment of purulent and nonpurulent SSTIs
  • Logistical challenges with IV and oral antibiotics
  • Pros and cons of various locations of care
  • Data supporting the safety and efficacy of long-acting lipoglycopeptides for treatment of SSTIs
  • Use of long-acting lipoglycopeptides in special populations of interest, including patients with obesity, diabetes, and injection drug use
  • Overall place in therapy of long-acting lipoglycopeptides for SSTIs

 

Faculty:

Kyle Molina, PharmD, BCIDP
Infectious Diseases Clinical Pharmacist
Scripps Green Hospital
La Jolla, California

Link to full program: 


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Answering the Questions on Which HIV PrEP for Which Patient: Latesha Elopre and Jason Farley03 Jul 202300:26:07

In this episode, Latesha Elopre, MD, MSPH, and Jason Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN, answer questions about HIV PrEP including:

  • How long someone can receive PrEP and the monitoring that is needed over time
  • Recommendations for monitoring bone health while receiving oral PrEP
  • Treatment as prevention and PrEP efficacy data and options for people who inject drugs
  • The role of circumcision in HIV prevention
  • The use of PrEP in pregnancy
  • Concern for ART resistance if someone seroconverts while receiving PrEP, especially when using nondaily PrEP options
  • The possibility of using FTC/TAF on demand
  • Inequities in adherence and persistence
  • Cost considerations with different PrEP modalities
  • Recommendations for hospitalized patients receiving PrEP
  • PrEP considerations for patients with renal dysfunction and higher BMIs
  • PrEP efficacy based on site of exposure

Presenters:

Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
Assistant Dean of Diversity and Inclusion
General Medical Education
University of Alabama at Birmingham
Birmingham, Alabama

Jason Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN
Professor
School of Nursing
Johns Hopkins University
Nurse Practitioner
Department of Infectious Diseases
John G. Bartlett Specialty Practice
Baltimore, Maryland

Link to full program:
https://bit.ly/3Fqdgs9


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Q&A on Barriers to HIV PrEP: Pharmacist Perspectives27 Jun 202300:10:17

In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP, and Kevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCES, discuss key considerations to barriers to PrEP uptake, including:

  • Limited data on “on-demand” PrEP in cisgender women 
  • Strategies on improving communication with non‒English-speaking populations 
  • Role of pharmacists with injectable PrEP 
  • CDC PrEP guideline recommendations on routine HIV-1 RNA testing 
  • Engaging with pregnant persons who might want access to PrEP in the pharmacy setting
  • Oral PrEP efficacy based on adherence in cisgender women, including recent data presented at CROI 2023 by Marrazzo and colleagues

Presenters: 

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Associate Professor
Department of Pharmacy Practice
Midwestern University College of Pharmacy, Downers Grove Campus
Downers Grove, Illinois
System-Level HIV/ID Clinical Pharmacist
Ambulatory Pharmacy
Northwestern Medicine
Wheaton, Illinois

Kevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCES
Assistant Professor
Department of Pharmacotherapy and Clinical Research
University of South Florida
Clinical Pharmacist
Tampa General Medical Group
Tampa, Florida

Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.

Link to full program:
https://bit.ly/3ZjSFhg

Downloadable slides: 
https://bit.ly/3PsFNDt


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Older Adults: Overcoming HBV Barriers23 Jun 202300:39:55

In this episode, Robert S. Brown, Jr., MD, MPH; Nancy Reau, MD; and Eric, a person living with chronic hepatitis B, discuss solutions for overcoming barriers to HBV care in older adults, including:

  • Awareness of HBV and CHB in older adults
  • Updated HBV screening and vaccination recommendations
  • Monitoring of renal and bone disease
  • Adjustment of monitoring and treatment as a person with HBV ages

Presenters: 
Robert S. Brown, Jr., MD, MPH
Vincent Astor Distinguished 
Professor of Medicine
Chief, Division of Gastroenterology and Hepatology
Weill Cornell Medicine
New York, New York

Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Eric, person living with chronic hepatitis B

Link to downloadable slides: please link to VM404 downloadable slides when ready

Link to program: 
bit.ly/3L3Kz6l


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Hepatitis Delta in Focus: Episode 4 of Answering the Questions on Screening, Diagnosis, and Treatment22 Jun 202300:39:58

In this episode, Tarik Asselah, MD, PhD, and Ira Jacobson, MD, provide expert insight on HDV screening, diagnosis, and management, including:

  • Approach to screening
  • Barriers to screening (eg, test availability)
  • Disease progression and complications
  • Differentiating between coinfection and superinfection
  • Approach to treatment (eg, whom to treat and when, treatment options, considerations for combination therapy)
  • Management of patients with decompensated cirrhosis
  • Surrogate markers to measure treatment success
  • Role of correcting thrombocytopenia before initiating therapy

Faculty:

Tarik Asselah, MD, PhD
Professor of Medicine 
Department of Hepatology
Hôpital Beaujon
Université de Paris
Clichy, France

Ira Jacobson, MD
Professor of Medicine
NYU School of Medicine
Director of Hepatology
Division of Gastroenterology and Hepatology
NYU Langone Health
New York, New York

Link to full program: https://bit.ly/3yp1Lxf

 


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Preparing for the Fall: New RSV Vaccine Approvals19 Jun 202300:12:51

In this episode, Helen Y. Chu, MD, MPH, shares updates on RSV vaccines, including:

  • An overview of vaccine candidates under investigation
  • Recently FDA-approved RSV vaccines for older adults
  • Considerations for the next respiratory viral season
  • Coadministration of RSV vaccines with other respiratory viral vaccines (eg, influenza, SARS-CoV-2)
  • Target populations for RSV vaccination
  • RSV prevention in infants with the maternal vaccine and monoclonal

Faculty:

Helen Y. Chu, MD, MPH
Associate Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington 
School of Medicine
Seattle, Washington

Link to full program: https://bit.ly/3nb25xehttps://bit.ly/3nb25xe

Link to downloadable slides: https://bit.ly/3TsXym5


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Hepatitis Delta in Focus: Episode 3 of Answering the Questions on Screening, Diagnosis, and Treatment19 Jun 202300:42:02

In this episode, Nancy Reau, MD, and Heiner Wedemeyer, MD, provide expert insight on HDV management, including:

  • Use of noninvasive imaging or biopsy for staging liver disease
  • Screening for hepatocellular carcinoma
  • HBV treatment
  • Role of comedications (eg, erythropoietin, eltrombopag)
  • Approach to complex cases, such as patients with:
    • Significant fibrosis and low HDV RNA levels
    • Hepatitis delta antibody positivity, but HDV RNA negativity
    • HIV coinfection
    • Decompensated or recently decompensated cirrhosis

Faculty:

Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Heiner Wedemeyer, MD
Professor and Chairman
Department of Gastroenterology, Hepatology and Endocrinology 
Hannover Medical School
Hannover, Germany

Link to full program: 
http://bit.ly/3yp1Lxf


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Modifying ART in the Presence of Hyperlipidemia: Using HIV-ASSIST09 Jun 202300:11:58

In this episode, Maunank Shah, MD, PhD, discusses using HIV-ASSIST to optimize treatment for both HIV and hyperlipidemia. Listen as he covers:

  • Hyperlipidemia and cardiovascular disease risk among people living with HIV
  • Recommendations for lipid screening for people living with HIV
  • Using HIV-ASSIST to support ART treatment decisions for people living with HIV with comorbidities
  • How HIV-ASSIST prioritizes certain ART agents in the setting of hyperlipidemia, including:
    • Deciding between bictegravir, doravirine, dolutegravir, raltegravir, and rilpivirine vs boosted protease inhibitors, including darunavir
    • Deciding between tenofovir disoproxil fumarate and tenofovir alafenamide or abacavir
  • How HIV-ASSIST incorporates drug‒drug interaction data from the University of Liverpool HIV Drug Interactions Checker and the DHHS guidelines when considering the use of statin therapy with ART
  • How HIV-ASSIST further incorporates drug resistance data from the Stanford HIV Drug Resistance Database

Maunank Shah, MD, PhD 
Associate Professor 
Infectious Diseases 
Johns Hopkins University 
Baltimore, Maryland 

Link to full program: bit.ly/3pwaH2Y


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Burden of Skin and Soft Tissue Infections: Epidemiology, Clinical Presentation, and Diagnosis08 Jun 202300:18:00

In this episode, Martin Krsak, MD, MSc, FASAM, provides background and context on skin and soft tissue infections. Listen as he gives perspectives on:

  • Epidemiology and clinical outcomes
  • Economic impact
  • Bacterial etiology
  • Importance of appropriate antimicrobial prescribing
  • Clinical presentation
  • Severity classification and distinction between purulent and nonpurulent infections
  • Role of incision and debridement vs antimicrobial management
  • Complications to be ruled out prior to treatment

Faculty:
Martin Krsak, MD, MSc, FASAM
Associate Professor of Medicine
Division of Infectious Diseases 
University of Colorado School of Medicine
Denver, Colorado

Link to full program: 


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

How to Make Depression Care an Integral Part of HIV Care24 Jul 202400:50:58

In this episode, Bradley N. Gaynes, MD, MPH, and Glenn J. Treisman, MD, PhD, discuss the importance of screening, diagnosing, and treating depression in people living with HIV. They illustrate their discussion through a patient case and provide strategies for accomplishing this, including creation of a virtual network and employment of measurement-based care.

Presenters:

Bradley N. Gaynes, MD, MPH
Ray M. Hayworth, MD and Family Distinguished Professor
Professor of Psychiatry and Epidemiology
Director, Division of Global Mental Health
Co-Director, Physician Scientist Training Program
Department of Psychiatry
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Glenn J. Treisman, MD, PhD
Eugene Meyer III Professor of Psychiatry and Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland

Downloadable slides
https://bit.ly/3YgqqSO

Program
https://bit.ly/3WB2VCO

To get access to all of our new infectious disease podcast episodes, subscribe to the CCO infectious disease podcast channel on Apple Podcasts, Google Podcasts, or Spotify.  


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Choosing Between Initial ART Options: Answering the Questions06 Jun 202300:46:49

In this episode, Marta Boffito, MD, PhD, FRCP, and Michelle Cespedes, MD, MS, discuss initial ART options, including:

  • Recommended first-line ART options for most PWH according to DHHS, IAS-USA, EACS, BHIVA, and WHO guidelines 
  • Data for weight gain after ART initiation with different ARV classes and drugs
  • Weight gain disparities by race and gender after ART initiation
  • Data from the RESPOND study including risk factors for weight gain and CV event risk with INSTI vs non-INSTI–based ART 
  • The impact of INSTIs on CV events in the Swiss HIV Cohort study 
  • Recommendations for ART and contraception for PWH of childbearing potential 
  • Drug–drug interactions between first-line ART and contraceptive options 
  • Guideline-recommended first-line ART options in pregnancy with a discussion of how these regimens differ from those recommended for most PWH 

Marta Boffito, MD, PhD, FRCP 
Consultant Physician 
Clinical Director, HIV, Sexual and Gender Health, Dermatology 
Chelsea and Westminster Hospital NHS Foundation Trust 
Imperial College London 
London, United Kingdom 

Michelle Cespedes, MD, MS 
Professor of Medicine 
Division of Infectious Disease 
Department of Medicine 
Icahn School of Medicine at 
Mount Sinai 
New York, New York 

Link to full program: bit.ly/3HPu4Lk


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Choosing ART for HIV With HBV and HCV Coinfections: Using HIV-ASSIST30 May 202300:05:56

In this episode, Carolyn Chu, MD, MSc, FAAFP, AAHIVS, discusses using HIV-ASSIST to aid in the selection of an ART regimen for PWH coinfected with HBV and HCV. Listen as she covers:

  • How HIV-ASSIST supports ART selection in primary care
  • Updates to viral hepatitis recommendations including:  
  •              CDC HBV screening and testing recommendations
  •              AASLD simplified HCV treatment approach for PWH
  • HIV-ASSIST for managing HIV/HBV coinfections, including ensuring that NRTIs that are effective for both HIV and HBV are included in an ART regimen and alerting the user when an additional HBV treatment is needed 
  • HIV-ASSIST for managing HIV/HCV coinfections, including showing how the HIV-ASSIST tool incorporates drug‒drug interaction considerations from the University of Liverpool HIV Drug Interaction Checker

Carolyn Chu, MD, MSc, FAAFP, AAHIVS
Chief Clinical Officer
National Clinician Consultation Center
Professor
Clinical Family Community Medicine
University of California, San Francisco
San Francisco, California

Link to full program: bit.ly/3pwaH2Y

 

 

 

 


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Integrating New Data on LA ART From CROI 2023: Pharmacist Perspectives22 May 202300:10:24

In this episode, Amanda Binkley, PharmD, BCIDP, AAHIVP, and Nimish Patel, PharmD, PhD, AAHIVP, discuss clinically relevant data on long-acting ART from CROI 2023, including:

  • LA CAB + RPV in San Francisco’s Ward 86 Safety Net Clinic Serving Publicly Insured PWH
  • SOLAR: Randomized Switch to LA CAB + RPV From BIC/FTC/TAF

Amanda Binkley, PharmD, BCIDP, AAHIVP
Clinical Pharmacy Specialist 
Infectious Disease
Department of Pharmacy
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania

Nimish Patel, PharmD, PhD, AAHIVP
Professor
Department of Clinical Pharmacy
Skaggs School of Pharmacy & Pharmaceutical Sciences
University of California
La Jolla, California

Link to full program: bit.ly/3ZjSFhg


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Christine Katlama and Babafemi Taiwo: Answering the Questions on Optimizing Antiretroviral Therapy in Heavily Treatment–Experienced People With HIV16 May 202300:41:52

In this episode, Christine Katlama, MD, and Babafemi Taiwo, MBBS, discuss optimizing ART for people with HIV who are treatment experienced or failing a current ART regimen, including:

  • Recycling agents from the NRTI, NNRTI, INSTI, and PI classes in salvage ART regimens
  • Maintaining NRTIs in second-line and salvage ART regimens, including the use of 3TC, TFV, and ABC
  • ART regimen simplification
  • When to perform genotypic resistance testing, including for PWH who have been off ART
  • When to perform DNA genotyping for archived resistance testing
  • Considering LA CAB + RPV with prior NNRTI exposure, ART resistance, or past adherence concerns with oral ART
  • Using boosted DRV + DTG in salvage regimens
  • Switching from boosted PIs to INSTIs in PWH receiving second-line therapy
  • Second-line regimens with LA CAB + RPV failure 

Christine Katlama, MD 
Professor 
Sorbonne University APHP Paris 
Head, HIV/Hepatitis Clinical and Research Unit 
Department of Infectious Diseases 
Paris, France 

Babafemi Taiwo, MBBS 
Gene Stollerman Professor of Medicine 
Chief, Division of Infectious Diseases 
Northwestern University Feinberg School of Medicine 
Chicago, Illinois 

Link to full program: https://bit.ly/3Z44Gq3


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Preconception ART Selection: Using HIV-ASSIST11 May 202300:08:09

In this episode, Sonya Krishnan, MD, MHS, discusses using HIV-ASSIST to aid in the selection of an ART regimen for a virologically suppressed PWH who is planning a pregnancy. Listen as she covers:

  • How to input patient specific factors into the HIV-ASSIST tool
  • Discussion of available education sheets to review the data and recommendations for her current ART regimen in pregnancy
  • An explanation of why some regimens are ranked lower because of adherence factors such as increased pill burden or dosing frequency
  • Guidelines informing the HIV-ASSIST output, including DHHS and IAS-USA, and the frequency with which updates are incorporated
  • How to use the HIV-ASSIST output to guide regimen selection in pregnancy
  • Use of the HIV-ASSIST tool in shared decision-making and patient counseling

Sonya Krishnan, MD, MHS
Assistant Professor
Division of Infectious Diseases
Johns Hopkins University
Baltimore, Maryland

Link to full program: 
bit.ly/3pwaH2Y


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Long-Acting ART: Cabotegravir Plus Rilpivirine10 May 202300:27:13

In this episode, Ian Frank, MD, discusses long-acting HIV treatment with cabotegravir plus rilpivirine for people with HIV, including:

  • Efficacy data with every-8-week dosing
  • Real-world use in people with viremia 
  • Initiation and continuation strategies
  • Virologic failure data
  • Safety information

 

Presenter:

Ian Frank, MD

Associate Chief

Division of Infectious Diseases

Professor of Medicine

University of Pennsylvania

Philadelphia, Pennsylvania

To download the slides: https://bit.ly/3HX1GGn

 

To view the full online program: https://bit.ly/3ZjSFhg

 


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

COVID-19 Update: Independent Conference Coverage of ECCMID 202305 May 202300:36:36

In this episode, Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI, discusses new data on COVID-19 presented at ECCMID 2023, including:

  • Treatment in special populations
    • REDPINE: remdesivir in people with renal impairment hospitalized for COVID-19 pneumonia
    • Remdesivir and readmission for COVID-19 in immunocompromised patients
    • Molnupiravir vs nirmatrelvir plus ritonavir for COVID-19 with hematologic malignancy
  • Management of patients with severe disease
    • RECOVERY: higher-dose vs standard-dose corticosteroids for hospitalized patients with COVID-19
    • Real-world study of tocilizumab vs baricitinib for severe COVID-19
  • Novel antivirals
    • Ensitrelvir
    • Bemnifosbuvir
  •  Novel vaccines
    • NB2155
    • AZD2816/AZD1222
    • qNIV/CoV2373
    • GRT-R910
    • NVX-CoV2373 in people with HIV

Faculty:  
Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI
Professor of Microbial Diseases
Centre for Experimental Pathogen Host Research
University College Dublin
Dublin, Ireland

Content based on an online CME/CE program supported by independent educational grants from Gilead Sciences, Inc. and Novavax.  

Link to full program: 
bit.ly/3niXGJ6

Link to downloadable slides: 
bit.ly/3LUFejG


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

2023 Audio Recap: Principles of Outpatient COVID-19 Management03 May 202301:14:42

In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:

  • Current COVID-19 landscape
  • Rapid antigen tests and PCR tests
  • Risk stratification of patients who have a positive SARS-CoV-2 test
  • Antiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)
  • Long COVID

Presenters:
Renslow Sherer, MD
Director, International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois

Trinh P. Vu, PharmD, BCIDP
Clinical Pharmacy Specialist in Infectious Diseases
Department of Pharmaceutical Services
Emory University Hospital Midtown
Atlanta, Georgia

To download the slides: bit.ly/3oHKC09

To view the full online program: bit.ly/4201xcO


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Complicated Clinical Infections: Clinical Impact of New Data From ECCMID 202303 May 202300:30:05

In this episode, David van Duin, MD, PhD, FIDSA, FAST, discusses new data on complicated clinical infections presented at ECCMID 2023, including:

  • Gram-negative resistance
    • Pharmacokinetic and clinical outcomes in patients receiving meropenem/vaborbactam for KPC-producing carbapenem-resistant Enterobacterales infections
    • Comparative study of cefiderocol- vs colistin-containing regimens for CRAB VAP with concomitant bacteremia
    • Real-world use of imipenem/cilastatin/relebactam for the treatment of infections caused by multidrug-resistant organisms
  • Antimicrobial stewardship
    • Safety and efficacy of antibiotic de-escalation from an antipseudomonal β-lactam in patients with Enterobacterales BSIs in SIMPLIFY
    • The SOAB study comparing clinical outcomes of switching to oral antibiotics after IV lead-in therapy vs continuing IV therapy in patients with Enterobacterales BSIs
    • Data from REGARD-VAP on outcomes of shortened antibiotic treatment for VAP guided by clinical criteria
  • Investigational agents
    • Open-label study following ATTACK of patients with colistin-resistant CRAB infections receiving sulbactam/durlobactam
    • Summary of findings from EAGLE-2 and EAGLE-3 of gepotidacin for uncomplicated UTI treatment
    • Post hoc DOOR analysis of SURE-2 of sulopenem for the treatment of complicated UTIs

 

Faculty: 
David van Duin, MD, PhD, FIDSA, FAST 
Professor of Medicine 
Director, Immunocompromised Host Infecious Diseases Program 
Division of Infectious Diseases 
University of North Carolina 
Chapel Hill, North Carolina 

Content based on an online CME/CE program supported by an independent educational grant from Shionogi Inc. 

Link to full program: https://bit.ly/3niXGJ6

Link to downloadable slides: https://bit.ly/3Hx0ppn


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

2023 Audio Recap: Practical Case Studies in Outpatient COVID-19 Management02 May 202300:57:16

In this episode, Tracey Piparo, PA-C, and Renslow Sherer, MD, discuss cases of nonhospitalized patients with COVID-19, including:

  • Young, healthy patient with no risk factors
  • Young, healthy patient with risk factors
  • Older patient with immunocompromise
  • Older patient with renal dysfunction
  • Patient experiencing hypoxia 

Presenters: 

Tracey Piparo, PA-C 
Department of Palliative Medicine 
RJWBarnabas 
New Brunswick, New Jersey 

Renslow Sherer, MD 
Director, International HIV Training Center 
Professor of Medicine 
Section of Infectious Diseases and Global Health 
Department of Medicine 
University of Chicago 
Chicago, Illinois 

To download the slides: bit.ly/44cgH0q

To view the full online program: https://bit.ly/4201xcO


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Managing Weight Gain on ART27 Jun 202400:24:00

In this episode, Cristina Mussini, MD,and William R. Short, MD, MPH, FIDSA,discuss the potential role of ART in weight change among people living with HIV.

Listen to their conversation on whether ART switch can lead to weight loss after weight gain and how to counsel people living with HIV on weight loss options, including lifestyle modifications and nonpharmacologic methods.

Presenters

Cristina Mussini, MD
Director of Infectious Diseases Clinics​
Professor of Infectious Diseases​
University of Modena School of Medicine​
Modena, Italy

William R. Short, MD, MPH, FIDSA
Associate Director of the ​
HIV Clinical Trials Unit​
Associate Professor of Medicine​
Division of Infectious Diseases​
Perelman School of Medicine​
University of Pennsylvania​
Philadelphia, Pennsylvania

Follow along with the slides here.
https://bit.ly/3RLdrET

See the full program here.
https://bit.ly/450Ql2x

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast channel on Apple Podcasts, Google Podcasts, or Spotify.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Q&A: HDV Management Episode 226 Apr 202300:40:10

In this episode, Tatyana Kushner, MD, MSCE, and Stefan Zeuzem, MD, address key considerations when screening, diagnosing, and treating patients with HDV, such as:

  • Barriers to HDV screening, including limitations to AASLD guideline recommendations
  • Use of double reflex testing to improve HDV diagnosis
  • Considerations for repeat HDV testing in patients who are HBsAg positive who previously tested negative for HDV
  • Updated CDC recommendations for HBV screening for all adults using a triple panel test 
  • Staging advanced liver disease in patients with HDV
  • Indications for HDV treatment, including patients with low ALT levels and advanced or progressive liver disease
  • Treatment landscape for HDV
  • Personal experiences with use of pegylated interferon for HDV treatment, including considerations for use in patients with compensated cirrhosis
  • Updates on novel HDV therapies, including:
    • Summary of efficacy data on bulevirtide from clinical trials
    • Interpretation of results from D-LIVR, a phase III trial assessing the safety and efficacy of lonafarnib 

Link to full program: 
bit.ly/3yp1Lxf


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Overcoming HBV Barriers: Focus on Asian American People25 Apr 202300:52:07

In this episode, Joseph Lim, MD; Mindie H. Nguyen, MD, MAS, AGAF, FAASLD; and Jennifer Wild, MS, BSN, RN, OCN, discuss strategies for overcoming barriers to HBV care in Asian American people, including:

  • HBV-related stigma
  • Language barriers
  • Health insurance navigation

Presenters:

Joseph Lim, MD
Professor of Medicine 
Director, Clinical Hepatology
Vice-Chief, Section of Digestive Diseases
Yale University School of Medicine
New Haven, Connecticut 

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Professor of Medicine (GI & Hepatology, Liver Transplant) 
Professor of Epidemiology & Population Health (By Courtesy)
Director of Hepatology Fellowship 
Director of Hepatology Clerkship
Stanford University Medical Center
Palo Alto, California

Jennifer Wild, MS, BSN, RN, OCN 
Clinical Nurse
UCSF Helen Diller Family Comprehensive Cancer Center
GI Medical Oncology, Outpatient Hepatobiliary Program
Oakland, California

Link to downloadable slides: please link to VM401 downloadable slides when ready

Link to program: please link to HEP 2023 HBV Key Communities VM (PRP5676) when ready


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

African Immigrant People: Overcoming HBV Barriers25 Apr 202300:58:49

In this episode, Essa Mohamed, PhD; Daouda Ndiaye; and Ponni Perumalswami, MD, MS, discuss strategies for overcoming barriers to HBV care in African immigrant people, including:

  • HBV awareness and misconceptions
  • HBV-related stigma
  • Language barriers
  • Health insurance navigation

Presenters:  
Essa Mohamed, PhD
Clinical Researcher
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, Minnesota

Daouda Ndiaye
Patient Navigator

Ponni Perumalswami, MD, MS
Associate Professor of Internal Medicine
Division of Gastroenterology and Hepatology
University of Michigan
Ann Arbor, Michigan

Link to program: bit.ly/3L3Kz6l

 


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Individualizing HIV ART: Considerations for Weight Gain24 Apr 202300:05:36

In this episode, Daniel R. Kuritzkes, MD, discusses considerations for patients experiencing weight gain on antiretroviral therapy, including:

• Commonly implicated antiretroviral therapy regimens and patient populations

• Guideline recommendations for management of weight gain

Presenter:

Daniel R. Kuritzkes, MD
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Boston, Massachusetts

To download the slides: 
bit.ly/3odUA9C

To view the full online program: 
bit.ly/3ZjSFhg


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Rapid ART Initiation: Answering the Questions21 Apr 202300:49:13

In this episode, Isolde Butler, MD, and Brenda E. Crabtree Ramírez, MD, discuss rapid ART initiation for people newly diagnosed with HIV, including:

  • The HIV care continuum in the United States and Latin America
  • Barriers to HIV diagnosis, including stigma, discriminatory laws and policies, social determinants of health, and lack of access to healthcare
  • Factors that predict delayed care linkage and inconsistent HIV care and treatment
  • Improved clinical outcomes that have been shown with rapid ART initiation, first in low- and middle-income countries and now worldwide
  • Recommendations for rapid ART—and regimen choices—from the DHHS, IAS-USA, CENSIDA, EACS, and WHO
  • Recommendations for transitioning from PrEP to ART when someone seroconverts while receiving either oral PrEP or LA CAB for PrEP
  • Barriers to rapid ART initiation in their individual care settings
  • The future of LA injectable ART for initial treatment and rapid initiation

Isolde Butler, MD
Chief Medical Officer
CrescentCare
New Orleans, Louisiana

Brenda E. Crabtree Ramírez, MD
Assistant Professor, HIV Program
Department of Infectious Diseases
Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán
Mexico City, Mexico

Link to full program: bit.ly/3HPu4Lk


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Individualizing HIV ART: Rapid Start13 Apr 202300:04:28

In this episode, Daniel R. Kuritzkes, MD, discusses considerations for rapid initiation of antiretroviral therapy in patients who are newly diagnosed with HIV, including:

  • Recommended regimens
  • Management of patients previously receiving PrEP
  • Timing of laboratory testing

Presenter:

Daniel R. Kuritzkes, MD
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Boston, Massachusetts

To download the slides: 
https://bit.ly/3odUA9C

To view the full online program: 
https://bit.ly/3ZjSFhg


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Perspectives From Asia on Advances in HIV Treatment and Prevention27 Mar 202300:21:38

In this episode, 2 HIV experts from the Asia-Pacific region share their thoughts on some of the most important new insights from HIV treatment and prevention research over the past year.

Specifically, the faculty discuss the role of newer innovations in HIV, including 2-drug oral antiretroviral therapy (ART) regimens, 2-drug long-acting injectable ART, and long-acting HIV pre-exposure prophylaxis in HIV care in the Asia-Pacific region, as well as the implications of weight gain with ART and important considerations related to the unique challenges associated with caring for the aging population of people with HIV in the region.

Presenters:

Anchalee Avihingsanon, MD, PhD
HIV-NAT, Thai Red Cross AIDS Research Centre
Pathumwan, Bangkok, Thailand 
Senior Clinical Trial
Medicine
Bangkok, Thailand

Reena Rajasuriar, BPharm, MPharm, PhD
Associate Professor
Department of Medicine
University of Malaya
Kuala Lumpur, Malaysia

Content based on an online program supported by an independent educational grant from Gilead Sciences, Inc. andViiV Healthcare. 

Link to full program: 
bit.ly/3Hz0jNa
 


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

RSV in Adults: How It Presents22 Mar 202300:12:24

In this episode, Angela Branche, MD, and Helen Y. Chu, MD, MPH, discuss the clinical presentation of respiratory syncytial virus (RSV) in adults and the importance of early detection, including:  

  • Clinical symptoms and presentation  
  • Complications, including exacerbations of cardiopulmonary diseases
  • Use of medical resources compared with other respiratory viruses
  • Diagnostic approaches and challenges
  • Treatment and management of RSV disease
  • Clinical impact of RSV awareness

Faculty:  

Angela Branche, MD

Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
University of Rochester
Rochester, New York

Helen Y. Chu, MD, MPH
Associate Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington  
School of Medicine
Seattle, Washington

Link to full program: 
bit.ly/3nb25xe

Link to downloadable slides:
bit.ly/3TsXym5


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

RSV in Adults: A Hidden Epidemic22 Mar 202300:10:43

In this episode, Angela Branche, MD, and Helen Y. Chu, MD, MPH, discuss the impact of respiratory syncytial virus (RSV) and describe those at risk for severe RSV disease, including: 

  • RSV prevalence and seasonality  
  • RSV burden throughout life, including burden in older adults
  • Comorbidities that increase the risk of RSV complications  
  • RSV transmission in the hospital and care home setting
  • Implications of risk factors for severe RSV on prevention and treatment    

Faculty: 

Angela Branche, MD
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
University of Rochester
Rochester, New York

Helen Y. Chu, MD, MPH
Associate Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington  
School of Medicine
Seattle, Washington

Link to full program: 
bit.ly/3nb25xe

Link to downloadable slides: 
bit.ly/3TsXym5


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Answering the Questions on Optimizing Antiretroviral Therapy in Heavily Treatment–Experienced People With HIV: José R. Arribas and Melissa Badowski21 Mar 202300:37:40

In this episode, José R. Arribas, MD, and Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP, discuss optimizing antiretroviral therapy (ART) for people with HIV who are treatment experienced or failing a current ART regimen, including:

  • The use of proviral DNA genotyping for switching therapy
  • Maintaining nucleos(t)ide reverse-transcriptase inhibitors after a first failure
  • The role of zidovudine in salvage regimens
  • The use of twice-daily darunavir with protease inhibitor resistance and twice-daily dolutegravir with integrase strand transfer inhibitor resistance
  • Simplification of regimens and long-acting therapies for people with HIV who are highly treatment experienced
  • Drug‒drug interactions that may warrant dosing changes to avoid resistance development
  • When to consider antiretrovirals with novel mechanisms of action, such as fostemsavir, ibalizumab, and lenacapavir
  • The logistics of dosing, administration, and development of a complete ART regimen that includes novel mechanism antiretrovirals
  • Addressing psychosocial factors to increase the chance of success on a new ART regimen
  • Drug‒drug interactions with novel mechanism agents
  • How common ART resistance is for people with HIV in their own practices
  • The possibility of using long-acting cabotegravir plus rilpivirine in people with viremia in the future
  • Addressing low-level viremia

José R. Arribas, MD
Professor of Medicine
Department of Medicine
Autónoma University School of Medicine
Head, Infectious Diseases Unit
Department of Internal Medicine
Hospital La Paz
Madrid, Spain

Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP
Clinical Associate Professor
Section of Infectious Diseases Pharmacotherapy 
Department of Pharmacy Practice
University of Illinois at Chicago, College of Pharmacy
Chicago, Illinois

Link to full program:
bit.ly/3Z44Gq3


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A Triumphant Return: Welcoming People Back to HIV Care17 Jun 202400:12:33

In this episode, Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, uses a case study to illustrate why patients living with HIV may disengage with their care and how best to reengage them once they present at the clinic, including discussion of:

  • The valid reasons patients have for disengaging with their HIV care
  • Why the return to care should be celebrated
  • How to support people living with HIV as they reengage in care
  • How to prevent future loss to follow-up

Presenter:
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
CEO, Desmond Tutu Health Foundation
Director, Desmond Tutu HIV Centre
Professor of Medicine
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa

Content based on an online CME program supported by an educational grant from Gilead Sciences, Inc.

Link to full program:
https://bit.ly/3xicSeF

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Answering the Questions on HIV PrEP Persistence16 Mar 202300:54:29

In this episode, Darrell H. S. Tan, MD, FRCPC, PhD, and Kenric Ware, PharmD, AAHIVP, discuss considerations for HIV pre-exposure prophylaxis (PrEP) persistence, including:

  • The PrEP continuum of care in the United States, including inequities in PrEP uptake and persistence by race
  • CDC PrEP guidance regarding PrEP indications
  • PrEP eligibility by regimen
  • Summary of renal, bone, and weight outcomes with different PrEP options
  • Data on HIV acquisition following PrEP discontinuation
  • Drug concentrations and recommendations for stopping long-acting cabotegravir for PrEP
  • Expanding PrEP options to facilitate adherence and persistence
  • Providing PrEP by telehealth

Presenters:

Darrell H. S. Tan, MD, FRCPC, PhD
Associate Professor
Division of Infectious Diseases
University of Toronto
Clinician-Scientist
Division of Infectious Diseases
St. Michael’s Hospital
Toronto, Canada

Kenric Ware, PharmD, AAHIVP
Associate Professor
Department of Pharmacy Practice
South University
Savannah, Georgia
Chairperson, Pharmacist
Board of Directors
Joseph H. Neal Health Collaborative
Columbia, South Carolina

Link to full program:
https://bit.ly/3HPu4Lk


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Answering Questions on Which HIV PrEP for Which Patient: Carolyn Chu and Samantha Strong15 Mar 202300:31:49

In this episode, Carolyn Chu, MD, MSc, FAAFP, AAHIVS, and Samantha Strong, PharmD, BCACP, AAHIVP, CDCES, answer questions including:

  • Strategies to improve disparities in pre-exposure prophylaxis (PrEP) access in difficult-to-reach populations 
  • Key remaining questions related to PrEP options for cisgender women and people who inject drugs
  • Concerns about resistance at seroconversion in patients with suboptimal PrEP compliance
  • Implementation of molecular screening for patients receiving PrEP
  • Expectations for weight gain and patient counseling points

Presenters:

Carolyn Chu, MD, MSc, FAAFP, AAHIVS
Chief Medical Officer
American Academy of HIV Medicine
Chief Clinical Officer
National Clinician Consultation Center

Samantha Strong, PharmD, BCACP, AAHIVP, CDCES 
Clinical Director of Pharmacy
Nevada Health Centers
Las Vegas, Nevada

Link to full program: 
https://bit.ly/3Fqdgs9


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Hepatitis Delta in Focus: Episode 1 of Answering the Questions on Screening, Diagnosis, and Treatment08 Mar 202300:22:43

In this episode, Maria Buti, MD, and Richard H. Davis, PA-C, address key considerations when screening, diagnosing, and treating patients with hepatitis delta virus (HDV), such as:

  • Barriers to screening 
  • HDV screening based on patient risk factors 
  • Universal screening for all patients with positive hepatitis B surface antigen (HBsAg)
  • Reflex testing 
  • Availability of commercial testing
  • Monitoring suggestions in HBsAg positive and HDV antibody positive patients with negative HDV RNA
  • Limitations to evaluating advanced fibrosis in patients with HDV
  • Data on novel HDV therapies (eg, bulevirtide and lonafarnib)
  • Extending HDV therapy (eg, peginterferon) based on treatment response
  • Stopping rules (eg, HDV RNA negativity, HBsAg loss) for discontinuing HDV therapy

Faculty:

Maria Buti, MD
Professor of Medicine
Hospital Universitario Vall d’Hebron
Barcelona, Spain

Richard H. Davis, PA-C
Senior PA
Gastroenterology
University of Florida
UF Health
Gainesville, Florida

Link to full program: 
http://bit.ly/3yp1Lxf


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

© My Podcast Data